Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis.

Transplantation - 27 Dec 2010

Chou Sunwen, Marousek Gail, Boivin Guy, Goyette Nathalie, Farhan Mahdi, Ives Jane A L, Elston Robert

Abstract excerpt

BACKGROUND: In a phase III controlled trial IMproved Protection Against Cytomegalovirus in Transplantation (IMPACT) comparing 200 with 100 days of valganciclovir prophylaxis in 318 cytomegalovirus D+/R- kidney transplant recipients, an equal number of patients (n=3 per arm) had known ganciclovir resistance mutations detected during viral breakthrough. In addition, many other viral sequence variants were observed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Base Sequence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytomegalovirus

Share to Cytomegalovirus Infections

Share to Follow-Up Studies

Share to Ganciclovir

Share to Genetic Variation

Share to Time Factors

Source

Identifiers

PMID: 21030903
DOI: 10.1097/TP.0b013e3181fdd9d2

Genes

IMPACT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis.PMID 21030903Read ↗

Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis.Semantic proximity Read ↗

Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.Semantic proximity Read ↗

Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.Semantic proximity Read ↗

Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.Semantic proximity Read ↗

Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)Semantic proximity Read ↗

Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.Semantic proximity Read ↗

Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis.Semantic proximity Read ↗

Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.Semantic proximity Read ↗

Drug-resistant cytomegalovirus: clinical implications of specific mutations.Semantic proximity Read ↗

Cytomegalovirus antiviral resistance: characterization of results from clinical specimens.Semantic proximity Read ↗

Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing.Semantic proximity Read ↗

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.